Morphine suppresses lung cancer cell proliferation through the interaction with opioid growth factor receptor: An in vitro and human lung tissue study

Anesthesia and Analgesia

Volumn 123, Issue 6, 2016, Pages 1429-1436

  Kim, Ji Yeon ^a   Ahn, Hyun Joo ^a   Kim, Jin Kyoung ^a   Kim, Jhingook ^a   Lee, Sang Hyun ^a   Chae, Hyun Byung ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE SULFATE; MU OPIATE RECEPTOR; OPIATE RECEPTOR; OPIOID GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; METHIONINE-ENKEPHALIN RECEPTOR; MORPHINE; NARCOTIC ANALGESIC AGENT; OPRM1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL COUNT; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; LUNG PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL LUNG CARCINOMA; ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGONISTS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANALGESICS, OPIOID; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MORPHINE; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84966709720     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000001293     Document Type: Article

References (28)

1. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105: 660-4
2. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008; 109: 180-7
3. Scavonetto F, Yeoh TY, Umbreit EC, Weingarten TN, Gettman MT, Frank I, Boorjian SA, Karnes RJ, Schroeder DR, Rangel LJ, Hanson AC, Hofer RE, Sessler DI, Sprung J. Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. Br J Anaesth 2014; 113(Suppl 1): i95-102
4. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI; ANZCA Trials Group Investigators. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 2011; 342: d1491
5. Sessler DI, Ben-Eliyahu S, Mascha EJ, Parat MO, Buggy DJ. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp Clin Trials 2008; 29: 517-26
6. Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011; 30: 225-38
7. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105: 106-15
8. Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 2011; 113: 1353-64
9. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112: 558-67
10. Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One 2014; 9: e91577
11. Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor and organ development in rat and human embryos. Brain Res 1999; 839: 313-22
12. Sassani JW, Zagon IS, McLaughlin PJ. Opioid growth factor modulation of corneal epithelium: uppers and downers. Curr Eye Res 2003; 26: 249-62
13. McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 1999; 14: 991-8
14. Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1154-61
15. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002; 38: 351-76
16. Sverrisdóttir E, Foster DJ, Upton RN, Olesen AE, Lund TM, Gabel-Jensen C, Drewes AM, Christrup LL, Kreilgaard M. Modelling concentration-analgesia relationships for morphine to evaluate experimental pain models. Eur J Pharm Sci 2014; 66C: 50-8
17. Sueoka E, Sueoka N, Kai Y, Okabe S, Suganuma M, Kanematsu K, Yamamoto T, Fujiki H. Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF-kappaB activation. Biochem Biophys Res Commun 1998; 252: 566-70
18. Zagon IS, Hytrek SD, McLaughlin PJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 1996; 271: R511-8
19. Fanning J, Hossler CA, Kesterson JP, Donahue RN, McLaughlin PJ, Zagon IS. Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer. Gynecol Oncol 2012; 124: 319-24
20. McLaughlin PJ, Zagon IS. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease. Biochem Pharmacol 2012; 84: 746-55
21. McLaughlin PJ, Stack BC Jr, Levin RJ, Fedok F, Zagon IS. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck. Cancer 2003; 97: 1701-10
22. Zagon IS, Kreiner S, Heslop JJ, Conway AB, Morgan CR, McLaughlin PJ. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int J Oncol 2008; 33: 317-23
23. Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett 2002; 187: 121-7
24. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGFOGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 2008; 7: 5
25. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGFOGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 2009; 20: 319-27
26. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res 2007; 67: 10511-8
27. Qin Y, Chen J, Li L, Liao CJ, Liang YB, Guan EJ, Xie YB. Exogenous morphine inhibits human gastric cancer MGC-803 cell growth by cell cycle arrest and apoptosis induction. Asian Pac J Cancer Prev 2012; 13: 1377-82
28. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth 2014; 113(Suppl 1): i103-8